SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : The Art of Investing -- Ignore unavailable to you. Want to Upgrade?


To: Sun Tzu who wrote (3242)1/11/2022 10:46:31 AM
From: Sun Tzu  Read Replies (1) | Respond to of 10688
 
The Chefs' Warehouse Provides 2022 Net Sales Guidance
BY MT Newswires
— 10:17 AM ET 01/11/2022
10:17 AM EST, 01/11/2022 (MT Newswires) -- The Chefs' Warehouse ( CHEF ) said in a regulatory filing on Tuesday that it expects full-year 2022 net sales of $2.1 billion to $2.2 billion.

Five analysts polled by Capital IQ project full-year 2022 revenue of $2 billion.

Adjusted EBITDA for the full year is projected to be between $99 million and $111 million, while gross profit is pegged at $494 million to $517 million.

Shares of the company declined 1% during the recent trading activity.

Price: 31.35, Change: -0.33, Percent Change: -1.04



To: Sun Tzu who wrote (3242)5/5/2022 1:38:12 PM
From: Sun Tzu  Read Replies (2) | Respond to of 10688
 
Royalty Pharma Plc Cl A (RPRX) reported 1st Quarter March 2022 earnings of $0.61 per share on revenue of $562.0 million. The consensus earnings estimate was $0.72 per share on revenue of $599.8 million. Revenue fell 1.9% compared to the same quarter a year ago.

Repros Therapeutics Inc is a development stage biopharmaceutical company. The Company is engaged in the development of new drugs to treat hormonal and reproductive system disorders.